Wanbury Limited share price
NSE: WANBURY · ISIN INE107F01022
Key numbers
- Market cap
- ₹ 784 Cr
- Current price
- ₹ 224.15
- 52-week high / low
- ₹ 359 / 162
- Stock P/E
- 13.8
- Book value
- ₹ 48.3
- Dividend yield
- 0.00%
- ROCE
- 29.7%
- ROE
- 64.9%
- Debt to equity
- 1.55
- Sales growth (3 yrs)
- 8.9%
- Profit growth (3 yrs)
- -
- 1-year return
- -10.2%
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API portfolio includes Metformin Hcl, Sertraline Hcl, Tramadol Hcl, Mefenamic Acid , Metformin Hcl DC, Diphenhydramine Citrate, Paroxetine, Diphenhydramine Hcl, and Anaesthetic API. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was founded in 1988 and is headquartered in Navi Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 163 | 160 | 162 | 165 | 166 |
| Operating profit | 24 | 26 | 27 | 30 | 16 |
| Net profit | 13 | 15 | 16 | 22 | 3 |
| EPS (₹) | 4.12 | 4.58 | 4.52 | 7.26 | 0.93 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.